AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra for treating adult patients with...
At its annual R&D Day, Moderna MRNA announcedseveral updates about the advancements in its pipeline and its business outlook for the next four years.MRNA to Cut R&D Costs, Stops Five Pipeline ProgramsManagement...
GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint.Data from the...
While technology stocks continue to struggle, stocks in the lucrative over-the-counter healthcare products sector are thriving. One prominent such name is Haleon. Its stock has jumped more than 22% over...
Shares of Vaxcyte PCVX rose more than 36% on Tuesday after it reported positive top-line results from a phase I/II study on VAX-31, which is an investigational 31-valent pneumococcal conjugate vaccine...
GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has been approved...
GSK GSK stock has risen 18.5% so far this year compared with an increase of 27.1% for the industry. The stock has also been consistently trading above its 50-day and 200-day moving averages since mid-August.GSK...
The anticipated 2027 Medicare drug negotiations are expected to impact several blockbuster drugs, with Novo Nordisk’s (NOVO) Ozempic, Pfizer’s (PFE) Ibrance and Xtandi, and GSK’s (GSK) Trelegy Ellipta...
Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...